163 related articles for article (PubMed ID: 15481852)
1. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease.
Yonemura K; Ohtake T; Matsushima H; Fujigaki Y; Hishida A
Clin Nephrol; 2004 Sep; 62(3):202-7. PubMed ID: 15481852
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Ratio of serum levels of 1,25-dihydroxyvitamin D3 and parathyroid hormone for the diagnosis and treatment of tuberculous peritonitis in a chronic kidney disease patient: a case report].
Oka H; Miishima N; Yoshitomi R; Mizobuchi T; Kamimura T; Sugawara K; Harada A
Nihon Jinzo Gakkai Shi; 2010; 52(5):584-9. PubMed ID: 20715591
[TBL] [Abstract][Full Text] [Related]
4. Lack of relationship between parathyroid hormone and 1,25-dihydroxyvitamin D in chronic renal failure.
Rudnicki M; McNair P; Transbøl I; Nielsen B
Nephron; 1991; 58(2):144-9. PubMed ID: 1865969
[TBL] [Abstract][Full Text] [Related]
5. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
Schömig M; Ritz E
Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
[TBL] [Abstract][Full Text] [Related]
6. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
Mortensen BM; Aarseth HP; Ganss R; Haug E; Gautvik KM; Gordeladze JO
Bone; 1993; 14(2):125-31. PubMed ID: 8334029
[TBL] [Abstract][Full Text] [Related]
7. Serum ionized calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal postmenopausal women.
Dawson-Hughes B; Harris S; Dallal GE
J Bone Miner Res; 1991 May; 6(5):461-8. PubMed ID: 2068951
[TBL] [Abstract][Full Text] [Related]
8. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
10. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of parathyroid hormone on the renal 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 production of young and adult rats.
Armbrecht HJ; Wongsurawat N; Zenser TV; Davis BB
Endocrinology; 1982 Oct; 111(4):1339-44. PubMed ID: 6981502
[TBL] [Abstract][Full Text] [Related]
12. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
13. Regulation of 1,25-dihydroxyvitamin D3 by calcium in the parathyroidectomized, parathyroid hormone-replete rat.
Weisinger JR; Favus MJ; Langman CB; Bushinsky DA
J Bone Miner Res; 1989 Dec; 4(6):929-35. PubMed ID: 2610024
[TBL] [Abstract][Full Text] [Related]
14. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D Metabolites and Their Association with Calcium, Phosphorus, and PTH Concentrations, Severity of Illness, and Mortality in Hospitalized Equine Neonates.
Kamr AM; Dembek KA; Reed SM; Slovis NM; Zaghawa AA; Rosol TJ; Toribio RE
PLoS One; 2015; 10(6):e0127684. PubMed ID: 26046642
[TBL] [Abstract][Full Text] [Related]
16. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
Soliman E; Canaff L; Fox J; Hendy GN
Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
[TBL] [Abstract][Full Text] [Related]
17. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
18. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion.
Brown AJ; Ritter C; Slatopolsky E; Muralidharan KR; Okamura WH; Reddy GS
J Cell Biochem; 1999 Apr; 73(1):106-13. PubMed ID: 10088729
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic metabolic alkalosis on Ca2+, PTH and 1,25(OH)2D3 in the rat.
Bushinsky DA; Kittaka MK; Weisinger JR; Langman CB; Favus MJ
Am J Physiol; 1989 Oct; 257(4 Pt 1):E578-82. PubMed ID: 2801937
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone modulation of 25-hydroxyvitamin D3 metabolism by cultured chick kidney cells is mimicked and enhanced by forskolin.
Henry HL
Endocrinology; 1985 Feb; 116(2):503-10. PubMed ID: 2981664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
